Skip to content
Brain & Nerves — Anti-amyloid antibodies

Lecanemab

Prescription only

Infusion that modestly slows early Alzheimer's.

Starts working
Varies
Half-life
—
In use since
2023
Pregnancy
Usually avoided

Overview

Lecanemab is an antibody that clears amyloid plaques and slowed decline by about a quarter over 18 months in early Alzheimer's disease. It requires regular MRI scans because it can cause brain swelling and small bleeds, and is not suitable for everyone.

Conditions it's used for

How it works

Helps the brain's immune system clear sticky amyloid protein.

Lecanemab belongs to the Anti-amyloid antibodies. How Anti-amyloid antibodies work: tag sticky amyloid protein so the brain's immune cells clear it, modestly slowing decline.

Uses

  • Early Alzheimer's disease (mild cognitive impairment or mild dementia) with confirmed amyloid

Available as: iv infusion every 2 weeks, subcutaneous autoinjector (maintenance).

Typical dose

Adults
10 mg/kg IV every 2 weeks; maintenance options include less frequent infusions or weekly injections.

Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.

Side effects

Common

Often mild and may settle with time

  • Infusion reactions
  • Headache
  • ARIA on MRI (often without symptoms)

Serious — get medical help

Uncommon, but need prompt attention

  • Brain swelling or bleeding (ARIA), higher with two copies of APOE4
  • Serious bleeds with blood thinners

Warnings

  • Genetic APOE4 testing and MRI before and during treatment
  • Generally avoided with anticoagulants

Interactions

  • Anticoagulants and thrombolytics — brain bleeding risk
Check Lecanemab against your own medicines

Pregnancy and breastfeeding

Usually avoided

Not studied.

Breastfeeding advice can differ from pregnancy advice — check with a pharmacist, or the LactMed database.

Brand names

United States
Leqembi, Leqembi Iqlik
United Kingdom
Leqembi
Europe
Leqembi

Examples only; many generic versions exist. The same brand name can mean different products in different countries.

History

  1. 2023

    Accelerated, then full, US approval.

  2. 2024

    Approved in the UK and, in 2025, the EU — though NHS England did not fund it.

  3. 2025

    A subcutaneous autoinjector for maintenance approved in the US.

A similar antibody, donanemab (Kisunla), was approved in the US in 2024 and can be stopped once plaques clear.

Common questions

Does it reverse memory loss?

No — it slows the rate of decline in early disease; it doesn't restore lost function.

Do I need a prescription for Lecanemab?

Yes — Lecanemab is prescription-only in most countries.

Can I take Lecanemab during pregnancy?

Usually avoided. Not studied. Always check with a doctor or midwife.

Sources and official information

Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.